Girl Planting seeds

New Study is “Chilling Commentary” on Future of Antibiotics

The health care market is failing to support new antibiotics used to treat some of the world’s most dangerous, drug-resistant “superbugs,” according to a new analysis by University of Pittsburgh School of Medicine infectious disease scientists.  In a study published today in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology, investigators used nationwide prescription data to determine that the current annual U.S. sales of new antibiotics to treat carbapenem-resistant Enterobacteriaceae (CRE), one of the world’s most insidious drug-resistant bacteria, is about $101 million annually — significantly short of the $1 billion believed to be necessary to assure the financial viability of a new antibiotic. Even if new anti-CRE agents were used as widely as possible to treat CRE infections, the projected market size is only $289 million.  Read more.....

 

Back

 
 
close (X)